LPA and coronary artery disorder: In a pre-specified analysis of the phase III randomized FOURIER trial, evolocumab reduced the risk of CHD death, MI or urgent revascularization by 23% (HR, 0.77; 95% CI, 0.67–0.88) in patients with a higher-than-median level of Lp(a) at baseline, and by 7% (HR, 0.93; 95% CI, 0.80–1.08; Pinteraction = 0.07) in patients with a Lp(a) level not exceeding the median at baseline (70).